Catalent has signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals for LUPKYNIS (voclosporin), a drug to treat adult patients with lupus nephritis (LN). LUPKYNIS was approved by the U.S. FDA in January 2021 for use in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN, and is the first FDA-approved oral therapy for LN. Catalent will manufacture LUPKYNIS as a softgel dosage form at its pharmaceutical softgel center of excellence in St. Petersburg, FL. LN causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events, and death. It is one of the most serious and common complications of the autoimmune disease systemic lupus erythematosus (SLE). Approximately 40% of patients with SLE develop LN at some point in their lifetime, and approximately a third have LN when they are diagnosed with SLE.